Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks

The efficacy of efgartigimod is comparable to IVIG therapy in improving acute symptoms of AQP4-IgG-positive NMOSD. Efgartigimod could be an elegant alternative to IVIG therapy, and no serious adverse events were observed during infusion.